- Home
- PAVM vs GRML Comparison
PAVM vs GRML Comparison
Compare PAVM & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAVM | GRML |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | 41 | 5 |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.1M | 51.5M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PAVM | GRML |
|---|---|---|
| Price | $6.50 | $0.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $65.00 | N/A |
| AVG Volume (30 Days) | 13.7K | ★ 3.1M |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $603.94 | N/A |
| Revenue Next Year | $33.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.27 |
| 52 Week High | $28.44 | $0.55 |
Technical Indicators
Market Signals| Indicator | PAVM | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 31.05 | 42.43 |
| Support Level | $6.11 | $0.31 |
| Resistance Level | $10.98 | $0.43 |
| Average True Range (ATR) | 0.40 | 0.05 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 11.19 | 8.42 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
About GRML Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.